Home » Topics » Regulatory » EMA

EMA
RSS

Polaris' ADI-PEG20 receives E.U. orphan drug status for MPM

Dec. 22, 2014

CCX-168 receives European orphan designation for ANCA-associated vasculitis

Dec. 9, 2014

EMA determines no evidence that Fluad caused deaths in Italy

Dec. 9, 2014

Bayer files for E.U. approval of BAY-81-8973 for hemophilia A

Dec. 5, 2014

EMA starts review of MAA of NPS Pharmaceuticals' Natpar

Dec. 3, 2014

EMA grants ALS candidate TW-001 orphan drug designation

Dec. 2, 2014

Karyopharm confirms additional orphan designations for selinexor in the E.U.

Dec. 2, 2014

E.U. regulatory authorities investigate adverse events in patients who received Fluad

Dec. 2, 2014

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Dec. 1, 2014

LCZ-696 granted accelerated assessment by CHMP in Europe

Dec. 1, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...